Literature DB >> 19740120

Nitroglycerin provocation in normal subjects is not a useful human migraine model?

J F Tvedskov1, H K Iversen, J Olesen, P Tfelt-Hansen.   

Abstract

Provoking delayed migraine with nitroglycerin in migraine sufferers is a cumbersome model. Patients are difficult to recruit, migraine comes on late and variably and only 50-80% of patients develop an attack. A model using normal volunteers would be much more useful, but it should be validated by testing the response to drugs of known efficacy in acute migraine. Furthermore, treatment during headache rather than pretreatment is the most naturalist method. To fulfil these requirements we used continuous long-lasting infusion of glyceryl trinitrate (GTN) 0.2 microg kg-1 min-1 for 140 min and gave aspirin 1000 mg, zolmitriptan 5 mg or placebo to normal healthy volunteers. The design was double-blind, placebo-controlled three-way crossover. Our hypothesis was that these drugs would be effective in the treatment of the mild constant headache induced by long-lasting GTN infusion. The headaches did not fulfil the International Headache Society diagnostic criteria for migraine without aura. Moreover, there was no effect on headache of either zolmitriptan or aspirin. Thus our hypothesis was disproved and we conclude that our model is not valid for the testing of new acute antimigraine drugs. Our experiment suggests that headache caused by direct nitric oxide (NO) action in the continued presence of NO is very resistance to analgesics and to specific acute migraine treatments. This suggests that NO works very deep in the cascade of events associated with vascular headache, whereas tested drugs work higher in the cascade. The model suggested here should therefore be tested with other headache/migraine-provoking agents that supposedly work higher in the cascade of events. The need for human models persists, but the solution to this problem is still pending.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19740120     DOI: 10.1111/j.1468-2982.2009.02014.x

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  9 in total

Review 1.  Human models of migraine - short-term pain for long-term gain.

Authors:  Messoud Ashina; Jakob Møller Hansen; Bára Oladóttir Á Dunga; Jes Olesen
Journal:  Nat Rev Neurol       Date:  2017-10-06       Impact factor: 42.937

2.  Pharmacology of reflex blinks in the rat: a novel model for headache research.

Authors:  M G Jones; A P Andreou; S B McMahon; D Spanswick
Journal:  J Headache Pain       Date:  2016-10-21       Impact factor: 7.277

3.  Pharmacological Characterization of Orofacial Nociception in Female Rats Following Nitroglycerin Administration.

Authors:  Robert M Caudle; Stephanie L Caudle; Natalie D Flenor; Eric L Rohrs; John K Neubert
Journal:  Front Pharmacol       Date:  2020-12-03       Impact factor: 5.810

4.  A novel, injury-free rodent model of vulnerability for assessment of acute and preventive therapies reveals temporal contributions of CGRP-receptor activation in migraine-like pain.

Authors:  Caroline M Kopruszinski; Edita Navratilova; Juliana Swiokla; David W Dodick; Iain P Chessell; Frank Porreca
Journal:  Cephalalgia       Date:  2020-09-26       Impact factor: 6.292

5.  Comprehensive clinical phenotyping of nitroglycerin infusion induced cluster headache attacks.

Authors:  Diana Y Wei; Peter J Goadsby
Journal:  Cephalalgia       Date:  2021-02-20       Impact factor: 6.292

6.  TNFα levels and macrophages expression reflect an inflammatory potential of trigeminal ganglia in a mouse model of familial hemiplegic migraine.

Authors:  Alessia Franceschini; Sandra Vilotti; Michel D Ferrari; Arn M J M van den Maagdenberg; Andrea Nistri; Elsa Fabbretti
Journal:  PLoS One       Date:  2013-01-11       Impact factor: 3.240

7.  Brain natriuretic peptide constitutively downregulates P2X3 receptors by controlling their phosphorylation state and membrane localization.

Authors:  Anna Marchenkova; Sandra Vilotti; Elsa Fabbretti; Andrea Nistri
Journal:  Mol Pain       Date:  2015-11-14       Impact factor: 3.395

Review 8.  Triptans and CGRP blockade - impact on the cranial vasculature.

Authors:  Silvia Benemei; Francesca Cortese; Alejandro Labastida-Ramírez; Francesca Marchese; Lanfranco Pellesi; Michele Romoli; Anne Luise Vollesen; Christian Lampl; Messoud Ashina
Journal:  J Headache Pain       Date:  2017-10-10       Impact factor: 7.277

9.  Investigation of sumatriptan and ketorolac trometamol in the human experimental model of headache.

Authors:  Hashmat Ghanizada; Mohammad Al-Mahdi Al-Karagholi; Nanna Arngrim; Mette Mørch-Rasmussen; Matias Metcalf-Clausen; Henrik Bo Wiberg Larsson; Faisal Mohammad Amin; Messoud Ashina
Journal:  J Headache Pain       Date:  2020-02-24       Impact factor: 7.277

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.